Luliconazole for the treatment of fungal infections: an evidence-based review
(Source: Core Evidence)
Source: Core Evidence - September 24, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Luliconazole for the treatment of fungal infections: an evidence-based review
Deepshikha Khanna, Subhash Bharti Department of Dermatology, Chacha Nehru Bal Chikitsalaya (Childrens Hospital), Delhi, India Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this review, we summarize the in vitro data, animal studies, and clinical trial data relating to the use of topical luliconazole. Preclinical studies have demonstrated excellent activity against dermatophytes. Further...
Source: Core Evidence - September 24, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Luliconazole for treatment of fungal infections
Khanna D, Bharti S (Source: Core Evidence)
Source: Core Evidence - September 23, 2014 Category: Drugs & Pharmacology Source Type: research
Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy
This article reviews the available evidence to reflect on the place of colistimethate sodium in the therapy of chronic pulmonary infection in CF. Keywords: Pseudomonas aeruginosa, treatment, multiresistant strains, Gram-negative bacteria, colistin (Source: Core Evidence)
Source: Core Evidence - September 19, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Colistimethate sodium for chronic pulmonary infection in CF
Koerner-Rettberg C, Ballmann M (Source: Core Evidence)
Source: Core Evidence - September 18, 2014 Category: Drugs & Pharmacology Source Type: research
Brodalumab in moderate-to-severe psoriasis
Coimbra S, Figueiredo A, Santos-Silva A (Source: Core Evidence)
Source: Core Evidence - July 20, 2014 Category: Drugs & Pharmacology Source Type: research
Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
Susana Coimbra,1,2 Américo Figueiredo,3 Alice Santos-Silva2,41CESPU (Advanced Polytechnic and University Cooperative), Institute of Research and Advanced Training in Health Sciences and Technologies, Gandra-PRD, 2IBMC, Institute for Molecular and Cell Biology, University of Porto, Porto, 3Service of Dermatology, Hospital and University Centre of Coimbra (CHUC), University of Coimbra, Coimbra, 4Biochemistry Laboratory, Biological Sciences Department, Faculty of Pharmacy (FFUP), University of Porto, Porto, PortugalAbstract: Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a...
Source: Core Evidence - July 20, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Regorafenib and HCC
Ravi S, Singal AK (Source: Core Evidence)
Source: Core Evidence - July 16, 2014 Category: Drugs & Pharmacology Source Type: research
Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer
Sujan Ravi,1 Ashwani K Singal21Department of Internal Medicine, 2Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, AL, USAAbstract: Hepatocellular carcinoma (HCC) is the second-most common cause of cancer-related death in the world. In spite of HCC surveillance with repeated imaging, about 50% of patients are diagnosed at an advanced stage and are not amenable to curative treatment options. Sorafenib, a multikinase inhibitor, remains the standard of care for advanced HCC. Over the last 5 years, several other medications have been tested in Phase III trials. However, they have not...
Source: Core Evidence - July 16, 2014 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research
Treprostinil in pulmonary hypertension
Buckley MS, Berry AJ, Kazem NH, Patel SA, Librodo PA (Source: Core Evidence)
Source: Core Evidence - June 19, 2014 Category: Drugs & Pharmacology Source Type: research
